We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intercept Reports Phase III Sub-Study Liver Biopsy Data
Read MoreHide Full Article
Intercept Pharmaceuticals announced encouraging data from the POISE biopsy sub-study. Results from the study confirmed that long-term treatment with obeticholic acid (“OCA”) leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis (“PBC”) who have had an incomplete response to ursodeoxycholic acid (UDCA).
Shares of the company fell 32.7% compared with the industry’s decline of 8.1%.
The study showed that some patients who were treated with OCA had regression of fibrosis and even cirrhosis. The study showed that OCA leads to significant reductions in alkaline phosphatase (ALP)-the primary endpoint, that are predicted to improve clinical outcomes of patients with PBC who do not respond adequately to or do not tolerate UDCA. The majority (97%) of the patients who completed the double-blind phase of the POISE trial entered an open-label extension.
In the sub-study of the POISE phase III trial, paired biopsies adequate for analysis were obtained for 13 patients all of whom had liver fibrosis or cirrhosis at baseline. Prior biopsy studies have shown that patients who were not treated with, or have an inadequate response to UDCA — which is the current standard of care — are at significantly higher risk of fibrosis progression, liver failure, transplant and death. However, results from the study showed that 13 patients — all receiving treatment with UDCA at baseline — had paired biopsies that were adequate for analysis.
After three years of OCA treatment, majority of patients improved (n=6; 46%) or maintained (n=5; 38%) their histological stage, while two patients (15%) deteriorated. Of the four patients with baseline cirrhosis, three (75%) improved to fibrosis without cirrhosis while receiving OCA treatment.
Pruritus is the most common symptom in patients with PBC and was also the most common adverse event in the POISE phase III sub-study.
The company also looks forward to announcing the results of the phase IV COBALT study to further evaluate OCA’s effects on fibrosis regression and clinical outcomes in patients with PBC.
A few better-ranked stocks from the same space worth considering are Ligand Pharmaceuticals (LGND - Free Report) , Protagonist Therapeutics (PTGX - Free Report) and Catabasis Pharmaceuticals . Whlle Ligand and Protagonist sport a Zacks Rank #1 (Strong Buy), Catabasis carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved up $3.78 to $4.40 from $4.75 to $5.32 for 2018 and 2019, respectively, over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.88%. The company’s shares have rallied 57% over a year.
Protagonist’s loss estimates narrowed from $1.30 to 66 cents for 2018 and from $1.99 to $1.26 for 2019, over the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.95%.
Catabasis’ loss estimates narrowed from $1.09 to 92 cents for 2018 and from $1.76 to $1.48 for 2019, in the last 30 days. The company came up with a positive earnings surprise in all the preceding four quarters, with an average beat of 14.56%. The stock has rallied 23.9% so far this year.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
Intercept Reports Phase III Sub-Study Liver Biopsy Data
Intercept Pharmaceuticals announced encouraging data from the POISE biopsy sub-study. Results from the study confirmed that long-term treatment with obeticholic acid (“OCA”) leads to the reversal or stabilization of fibrosis/cirrhosis in patients with primary biliary cholangitis (“PBC”) who have had an incomplete response to ursodeoxycholic acid (UDCA).
Shares of the company fell 32.7% compared with the industry’s decline of 8.1%.
The study showed that some patients who were treated with OCA had regression of fibrosis and even cirrhosis. The study showed that OCA leads to significant reductions in alkaline phosphatase (ALP)-the primary endpoint, that are predicted to improve clinical outcomes of patients with PBC who do not respond adequately to or do not tolerate UDCA. The majority (97%) of the patients who completed the double-blind phase of the POISE trial entered an open-label extension.
In the sub-study of the POISE phase III trial, paired biopsies adequate for analysis were obtained for 13 patients all of whom had liver fibrosis or cirrhosis at baseline. Prior biopsy studies have shown that patients who were not treated with, or have an inadequate response to UDCA — which is the current standard of care — are at significantly higher risk of fibrosis progression, liver failure, transplant and death. However, results from the study showed that 13 patients — all receiving treatment with UDCA at baseline — had paired biopsies that were adequate for analysis.
After three years of OCA treatment, majority of patients improved (n=6; 46%) or maintained (n=5; 38%) their histological stage, while two patients (15%) deteriorated. Of the four patients with baseline cirrhosis, three (75%) improved to fibrosis without cirrhosis while receiving OCA treatment.
Pruritus is the most common symptom in patients with PBC and was also the most common adverse event in the POISE phase III sub-study.
The company also looks forward to announcing the results of the phase IV COBALT study to further evaluate OCA’s effects on fibrosis regression and clinical outcomes in patients with PBC.
Intercept Pharmaceuticals, Inc. Price
Intercept Pharmaceuticals, Inc. Price | Intercept Pharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
Intercept carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the same space worth considering are Ligand Pharmaceuticals (LGND - Free Report) , Protagonist Therapeutics (PTGX - Free Report) and Catabasis Pharmaceuticals . Whlle Ligand and Protagonist sport a Zacks Rank #1 (Strong Buy), Catabasis carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand’s earnings per share estimates have moved up $3.78 to $4.40 from $4.75 to $5.32 for 2018 and 2019, respectively, over the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.88%. The company’s shares have rallied 57% over a year.
Protagonist’s loss estimates narrowed from $1.30 to 66 cents for 2018 and from $1.99 to $1.26 for 2019, over the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 24.95%.
Catabasis’ loss estimates narrowed from $1.09 to 92 cents for 2018 and from $1.76 to $1.48 for 2019, in the last 30 days. The company came up with a positive earnings surprise in all the preceding four quarters, with an average beat of 14.56%. The stock has rallied 23.9% so far this year.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>